Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Apolo Website

Andrea B. Apolo, M.D.

Selected Publications

1)  Apolo AB, Kwiatkowski DJ.
Targeting molecular aberrations in urothelial carcinoma.
Am Soc Clin Oncol Educ Book. 2013: 195-9, 2013.
[Journal]
2)  Kohaar I, Porter-Gill P, Lenz P, Fu YP, Mumy A, Tang W, Apolo AB, Rothman N, Baris D, Schned AR, Ylaya K, Schwenn M, Johnson A, Jones M, Kida M, Silverman DT, Hewitt SM, Moore LE, Prokunina-Olsson L.
Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
J. Natl. Cancer Inst. 105: 69-73, 2013.
[Journal]
3)  Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF.
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
J. Clin. Oncol. 31: 724-30, 2013.
[Journal]
4)  Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF.
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with Cisplatin-based chemotherapy.
J. Natl. Cancer Inst. 105: 499-503, 2013.
[Journal]
5)  Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y.
Summary of the 6th annual bladder cancer think tank: New directions in urologic research.
Urol. Oncol. [Epub ahead of print], 2012.
[Journal]
6)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
J. Nucl. Med. 53: 1175-84, 2012.
[Journal]
7)  Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB.
Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.
Curr. Mol. Med. 12: 1125-41, 2012.
[Journal]
8)  Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM.
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.
Urol. Oncol. 30: 772-80, 2011.
[Journal]
9)  Apolo AB, Riches J, Schoder H, Akin O, Trout A, Milowsky MI, Bajorin DF.
Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer.
J Clin Oncol. 28: 3973-8, 2010.
[Journal]
10)  Apolo AB, Milowsky M, Bajorin DF.
Clinical states model for biomarkers in bladder cancer.
Future Oncol. 5: 977-92, 2009.
[Journal]
11)  Apolo AB, Pandit-Taskar N, Morris MJ.
Novel tracers and their development for the imaging of metastatic prostate cancer.
J. Nucl. Med. 49: 2031-41, 2008.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 8/15/2013.